Reported psychiatric adverse events among isotretinoin users: Monitoring priorities from a 20-year FDA Adverse Event...

Area of Science:

• Pharmacovigilance
• Psychiatry
• Dermatology

Background:

• Isotretinoin is associated with psychiatric adverse events (AEs).
• Prioritization of specific psychiatric AEs for monitoring beyond depression and suicide is unclear.
• Understanding these risks is crucial for patient safety during isotretinoin therapy.

Purpose of the Study:

• To identify and prioritize psychiatric adverse events (AEs) associated with isotretinoin treatment.
• To analyze the temporal patterns of these AEs.
• To inform clinical monitoring strategies for patients receiving isotretinoin.

Main Methods:

• Analysis of psychiatric AEs from the FDA Adverse Event Reporting System (FAERS) database (2004-2024).
• Disproportionality analysis using reporting odds ratios (RORs) to identify positive safety signals.
• Clinical priority scoring and time-to-onset analysis to rank and evaluate AE patterns.

Main Results:

• Over 19,000 isotretinoin-related psychiatric AEs were analyzed, revealing 50 positive signals with over 20 cases each.
• Twenty-five important signals were identified, including depressive disorders, suicide/self-injury, anxiety, mood changes, bipolar disorder, psychosis, and affective disorders.
• Acne patients showed a higher incidence of important signals, with a median time-to-onset of 80 days for moderate-priority events, indicating an early-onset pattern.

Conclusions:

• Mood disturbances, suicide/self-injury, and psychosis are critical psychiatric AEs requiring focused monitoring during isotretinoin treatment.
• Acne patients are a key population for intensified psychiatric monitoring.
• Implementing early and continuous monitoring strategies can help reduce isotretinoin-associated psychiatric harm.